Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | May 21, 2026 | May 26, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Patient Officer | February 15, 2019 | March 06, 2019 |
| Lunai Bioworks Inc.RENB · Entity 7981 | Director | June 25, 2024 | June 27, 2024 |
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.69 · Expires 2036-05-21 | Direct | 12,500 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 12,500 · Balance 12,500 F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.
GILEAD SCIENCES, INC.
Report date February 15, 2019 · Filed March 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,046 |
Reported balance
After 2019-02-15 transaction · row 1
1 source rowRow 1 · 2019-02-15 · Grant · Acquired 330 · Balance 58,046 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.01 · Expires 2029-03-01 | Direct | 9,640 |
Reported balance
After 2019-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-01 · Grant · Acquired 9,640 · Balance 9,640 F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 15,530 |
Reported balance
After 2019-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-01 · Grant · Acquired 1,890 · Balance 15,530 F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F4: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
Lunai Bioworks Inc.
Report date June 25, 2024 · Filed June 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase shares of common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2034-06-25 | Direct | 48,137 |
Reported balance
After 2024-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-25 · Grant · Acquired 48,137 · Balance 48,137 |
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,685 |
Reported balance
After 2026-06-20 transaction · row 1
1 source rowRow 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 47,685 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2017 Filed Aug 3, 2017 22:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,625 | $26.99 | $232,788.75 |
DisclosureSEC source: 0001127602-17-024923 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 34,500 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0001127602-17-024126 · form4.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,626 Underlying: Common Stock · 34,500 shares Expires 2018-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest over a five year period with 20% vesting July 30, 2009, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, and will be fully vested on July 30, 2013. Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,500 | $74.00 | $407,000.00 |
DisclosureSEC source: 0001127602-17-024126 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,488 Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 34,500 | $74.00 | $2,553,000.00 |
DisclosureSEC source: 0001127602-17-024126 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,988 Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 34,500 | $26.99 | $931,155.00 |
DisclosureSEC source: 0001127602-17-024126 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 22:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $71.06 | $355,295.00 |
DisclosureSEC source: 0001127602-17-023295 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,988 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F2 · price: Sale prices reported for the transactions reported here range from $70.61 to $71.57. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $65.02 | $325,113.50 |
DisclosureSEC source: 0001127602-17-020590 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,988 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F2 · price: Sale prices reported for the transactions reported here range from $65.01 to $65.05. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 01, 2017 Filed May 3, 2017 21:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $68.31 | $341,529.00 |
DisclosureSEC source: 0001127602-17-016652 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,988 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F2 · price: Sale prices reported for the transactions reported here range from $68.06 to $68.74. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $67.48 | $337,392.00 |
DisclosureSEC source: 0001127602-17-013648 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,988 F1 · price: Sale prices reported for the transactions reported here range from $67.20 to $67.77. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 21, 2017 Filed Mar 2, 2017 20:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 1,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009630 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,988 F1 · kind: Shares gifted to a donor advised fund. Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 02:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 6,577 | $70.31 | $462,428.87 |
DisclosureSEC source: 0001127602-17-007548 · form4.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,418 Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 02:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 2,776 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007548 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,995 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2014. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 02:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 4,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007548 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,219 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2015, and February 1, 2016. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2017 and December 31, 2018, respectively. Read SEC document |
| February 15, 2017 Filed Feb 22, 2017 02:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 315 | $59.33 | $18,688.95 |
DisclosureSEC source: 0001127602-17-007548 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,279 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 02:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 90,430 | $0.00 Strike: $72.25 | $0.00 |
DisclosureSEC source: 0001127602-17-004217 · form4.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,430 Underlying: Common Stock · 90,430 shares Expires 2027-02-02 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 20, 2017 Filed Feb 17, 2018 00:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | OtherCommon Stock | 14,435 | $71.01 | $1,025,029.35 |
DisclosureSEC source: 0001127602-18-006856 · form5.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,435 F1 · shares: Shares inherited from family trust Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 18:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $79.00 | $790,000.00 |
DisclosureSEC source: 0001127602-16-066869 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,964 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 20:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $81.84 | $409,220.00 |
DisclosureSEC source: 0001127602-16-063191 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP Comm&Acs ALA, Corp&Med Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,964 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: Sale prices reported for the transactions reported here range from $99.93 to $100.91. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 19, 2016 Filed Apr 21, 2016 17:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 35,874 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0001127602-16-049647 · form4.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,126 Underlying: Common Stock · 35,874 shares Expires 2018-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest over a five year period with 20% vesting July 30, 2009, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, and will be fully vested on July 30, 2013. Read SEC document |
| April 19, 2016 Filed Apr 21, 2016 17:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,126 | $100.00 | $412,600.00 |
DisclosureSEC source: 0001127602-16-049647 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,964 Read SEC document |
| April 19, 2016 Filed Apr 21, 2016 17:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 35,874 | $100.02 | $3,587,973.98 |
DisclosureSEC source: 0001127602-16-049647 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,090 F3 · price: Sale prices reported for the transactions reported here range from $100.00 to $100.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 19, 2016 Filed Apr 21, 2016 17:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 35,874 | $26.99 | $968,239.26 |
DisclosureSEC source: 0001127602-16-049647 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 01, 2016 Filed Apr 5, 2016 23:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $91.23 | $456,157.50 |
DisclosureSEC source: 0001127602-16-048908 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,090 F1 · price: Sale prices reported for the transactions reported here range from $91.11 to $91.34. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 14, 2016 Filed Mar 15, 2016 23:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $90.00 | $450,000.00 |
DisclosureSEC source: 0001127602-16-046404 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,090 F1 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 16, 2016 Filed Feb 19, 2016 00:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 32,786 | $91.15 | $2,988,443.90 |
DisclosureSEC source: 0001127602-16-042269 · form4.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,090 Read SEC document |
| February 16, 2016 Filed Feb 19, 2016 00:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 42,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-042269 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,876 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2013. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 16, 2016 Filed Feb 19, 2016 00:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 12,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-042269 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,262 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of performance share awards made to the Reporting Person on February 1, 2014, and February 1, 2015. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2016, and committee certifications respectively. Read SEC document |
| February 15, 2016 Filed Feb 19, 2016 00:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 248 | $76.02 | $18,853.95 |
DisclosureSEC source: 0001127602-16-042269 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,670 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 22:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,030 | $0.00 Strike: $84.05 | $0.00 |
DisclosureSEC source: 0001179110-16-018451 · edgar.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,030 Underlying: Common Stock · 75,030 shares Expires 2026-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 01, 2015 Filed Dec 3, 2015 18:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001179110-15-015666 · edgar.xml · derivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,742 Underlying: Common Stock · 10,000 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 01, 2015 Filed Dec 3, 2015 18:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,300 | $107.18 | $139,330.23 |
DisclosureSEC source: 0001179110-15-015666 · edgar.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,422 F5 · price: Sale prices reported for the transactions reported here range from $107.0911 to $107.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 01, 2015 Filed Dec 3, 2015 18:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,705 | $106.54 | $501,264.11 |
DisclosureSEC source: 0001179110-15-015666 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,722 F4 · price: Sale prices reported for the transactions reported here range from $106.04 to $107.03. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 01, 2015 Filed Dec 3, 2015 18:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,995 | $105.35 | $631,564.26 |
DisclosureSEC source: 0001179110-15-015666 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,427 F3 · price: Sale prices reported for the transactions reported here range from $104.93 to $105.75. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 01, 2015 Filed Dec 3, 2015 18:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $24.30 | $242,950.00 |
DisclosureSEC source: 0001179110-15-015666 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 19:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001179110-15-014439 · edgar.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,742 Underlying: Common Stock · 10,000 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 19:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,860 | $109.67 | $642,641.59 |
DisclosureSEC source: 0001179110-15-014439 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,422 F4 · price: Sale prices reported for the transactions reported here range from $109.4825 to $109.8624. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 19:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,140 | $109.10 | $669,865.40 |
DisclosureSEC source: 0001179110-15-014439 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,282 F3 · price: Sale prices reported for the transactions reported here range from $108.48 to $109.48. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 19:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $24.30 | $242,950.00 |
DisclosureSEC source: 0001179110-15-014439 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2015 Filed Oct 27, 2015 19:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001179110-15-014235 · edgar.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,742 Underlying: Common Stock · 5,000 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| October 26, 2015 Filed Oct 27, 2015 19:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $110.00 | $550,000.00 |
DisclosureSEC source: 0001179110-15-014235 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,422 Read SEC document |
| October 26, 2015 Filed Oct 27, 2015 19:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $24.30 | $121,475.00 |
DisclosureSEC source: 0001179110-15-014235 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2015 Filed Oct 7, 2015 17:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001179110-15-013906 · edgar.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,742 Underlying: Common Stock · 5,000 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| October 05, 2015 Filed Oct 7, 2015 17:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $100.00 | $500,000.00 |
DisclosureSEC source: 0001179110-15-013906 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,422 Read SEC document |
| October 05, 2015 Filed Oct 7, 2015 17:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $24.30 | $121,475.00 |
DisclosureSEC source: 0001179110-15-013906 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2015 Filed Oct 5, 2015 18:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001179110-15-013774 · edgar.xml · derivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,742 Underlying: Common Stock · 5,000 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| October 01, 2015 Filed Oct 5, 2015 18:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $98.58 | $29,573.01 |
DisclosureSEC source: 0001179110-15-013774 · edgar.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,422 F5 · price: Sale prices reported for the transactions reported here range from $98.55 to $98.59. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 01, 2015 Filed Oct 5, 2015 18:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,485 | $97.68 | $145,049.01 |
DisclosureSEC source: 0001179110-15-013774 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,722 F4 · price: Sale prices reported for the transactions reported here range from $97.4894 to $98.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 01, 2015 Filed Oct 5, 2015 18:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,215 | $97.09 | $506,308.18 |
DisclosureSEC source: 0001179110-15-013774 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,207 F3 · price: Sale prices reported for the transactions reported here range from $96.47 to $97.46. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 01, 2015 Filed Oct 5, 2015 18:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $24.30 | $121,475.00 |
DisclosureSEC source: 0001179110-15-013774 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2015 Filed Sep 17, 2015 19:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001104659-15-065754 · a4.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP, Corp & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,742 Underlying: Common Stock · 5,000 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.